WallStreetZenWallStreetZen

NASDAQ: CLGN
Collplant Biotechnologies Ltd Stock Forecast, Predictions & Price Target

Open Broker Account

Analyst price target for CLGN

Based on 2 analysts offering 12 month price targets for Collplant Biotechnologies Ltd.
Min Forecast
$17.00+141.13%
Avg Forecast
$21.50+204.96%
Max Forecast
$26.00+268.79%

Should I buy or sell CLGN stock?

Based on 1 analyst offering ratings for Collplant Biotechnologies Ltd.
Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CLGN stock forecasts and price targets.

Forecast return on equity

Is CLGN forecast to generate an efficient return?
Company
118.15%
Industry
18.78%
Market
118.57%
CLGN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CLGN forecast to generate an efficient return on assets?
Company
105.09%
Industry
14.1%
CLGN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CLGN earnings per share forecast

What is CLGN's earnings per share in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
-$0.34
Avg 2 year Forecast
$3.20
Avg 3 year Forecast
$3.08

CLGN revenue forecast

What is CLGN's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$12.0M+1,956.7%
Avg 2 year Forecast
$70.6M+12,037.46%
Avg 3 year Forecast
$106.1M+18,130.24%
CLGN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CLGN revenue growth forecast

How is CLGN forecast to perform vs Biotechnology companies and vs the US market?
Company
467.02%
Industry
23.75%
Market
8.46%
CLGN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CLGN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CLGN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CLGN$7.05$21.50+204.96%Strong Buy
TSHA$1.89$25.88+1,269.05%Strong Buy
EPIX$1.75$20.00+1,042.86%Strong Buy
SRZN$2.27$5.00+120.26%Hold
TLSA$0.78$4.00+412.82%Strong Buy

Collplant Biotechnologies Stock Forecast FAQ

Is Collplant Biotechnologies Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: CLGN) stock is to Strong Buy CLGN stock.

Out of 1 analyst, 1 (100%) are recommending CLGN as a Strong Buy, 0 (0%) are recommending CLGN as a Buy, 0 (0%) are recommending CLGN as a Hold, 0 (0%) are recommending CLGN as a Sell, and 0 (0%) are recommending CLGN as a Strong Sell.

If you're new to stock investing, here's how to buy Collplant Biotechnologies stock.

What is CLGN's earnings growth forecast for 2022-2024?

(NASDAQ: CLGN) Collplant Biotechnologies's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 8.67%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.42%.

Collplant Biotechnologies's earnings in 2022 is -$14,994,000.On average, 1 Wall Street analyst forecast CLGN's earnings for 2022 to be -$3,769,404, with the lowest CLGN earnings forecast at -$3,769,404, and the highest CLGN earnings forecast at -$3,769,404. On average, 1 Wall Street analyst forecast CLGN's earnings for 2023 to be $35,476,739, with the lowest CLGN earnings forecast at $35,476,739, and the highest CLGN earnings forecast at $35,476,739.

In 2024, CLGN is forecast to generate $34,146,361 in earnings, with the lowest earnings forecast at $34,146,361 and the highest earnings forecast at $34,146,361.

What is CLGN's revenue growth forecast for 2022-2024?

(NASDAQ: CLGN) Collplant Biotechnologies's forecast annual revenue growth rate of 467.02% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 23.75%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 8.46%.

Collplant Biotechnologies's revenue in 2022 is $582,000.On average, 1 Wall Street analysts forecast CLGN's revenue for 2022 to be $132,705,178, with the lowest CLGN revenue forecast at $132,705,178, and the highest CLGN revenue forecast at $132,705,178. On average, 1 Wall Street analysts forecast CLGN's revenue for 2023 to be $783,149,018, with the lowest CLGN revenue forecast at $783,149,018, and the highest CLGN revenue forecast at $783,149,018.

In 2024, CLGN is forecast to generate $1,176,275,634 in revenue, with the lowest revenue forecast at $1,176,275,634 and the highest revenue forecast at $1,176,275,634.

What is CLGN's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: CLGN) forecast ROA is 105.09%, which is higher than the forecast US Biotechnology industry average of 14.1%.

What is CLGN's Price Target?

According to 2 Wall Street analysts that have issued a 1 year CLGN price target, the average CLGN price target is $21.50, with the highest CLGN stock price forecast at $26.00 and the lowest CLGN stock price forecast at $17.00.

On average, Wall Street analysts predict that Collplant Biotechnologies's share price could reach $21.50 by Jun 13, 2023. The average Collplant Biotechnologies stock price prediction forecasts a potential upside of 204.96% from the current CLGN share price of $7.05.

What is CLGN's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: CLGN) Collplant Biotechnologies's current Earnings Per Share (EPS) is -$1.43. On average, analysts forecast that CLGN's EPS will be -$0.34 for 2022, with the lowest EPS forecast at -$0.34, and the highest EPS forecast at -$0.34. On average, analysts forecast that CLGN's EPS will be $3.20 for 2023, with the lowest EPS forecast at $3.20, and the highest EPS forecast at $3.20. In 2024, CLGN's EPS is forecast to hit $3.08 (min: $3.08, max: $3.08).

What is CLGN's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: CLGN) forecast ROE is 118.15%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.